StockData
Kiniksa Pharmaceuticals International, plc logo

Kiniksa Pharmaceuticals International, plc (KNSA) stock

KNSANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 14/30461% above fair value
$94.23−2.10 (-2.18%)

Close on Nov 16, 2026Market cap $14.81BP/E 72.5Yield –

Kiniksa Pharmaceuticals International enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Kiniksa Pharmaceuticals International's enterprise value was $7.32B on Nov 11, 2026, against $2.91B a year earlier. Over the last 5 years it ranged from $381.37M to $7.32B, with a median of $1.20B.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026$7.32B+160.6%
2025Dec 31, 2025$2.81B+130.9%
2024Dec 31, 2024$1.22B+17.3%
2023Dec 29, 2023$1.04B+23.4%
2022Dec 30, 2022$840.21M+39.0%
2021Dec 31, 2021$604.40M-9.8%
2020Dec 31, 2020$669.71M+108.5%
2019Dec 31, 2019$321.16M+98.0%
2018Dec 31, 2018$162.17M–

More Kiniksa Pharmaceuticals International figures

See a number that looks wrong?